Search

Your search keyword '"Kendra, Kari"' showing total 179 results
Start Over Author "Kendra, Kari" Publication Year Range Last 3 years
179 results on '"Kendra, Kari"'

1. Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial

Author

VanderWalde, Ari, Bellasea, Shay L, Kendra, Kari L, Khushalani, Nikhil I, Campbell, Katie M, Scumpia, Philip O, Kuklinski, Lawrence F, Collichio, Frances, Sosman, Jeffrey A, Ikeguchi, Alexandra, Victor, Adrienne I, Truong, Thach-Giao, Chmielowski, Bartosz, Portnoy, David C, Chen, Yuanbin, Margolin, Kim, Bane, Charles, Dasanu, Constantin A, Johnson, Douglas B, Eroglu, Zeynep, Chandra, Sunandana, Medina, Egmidio, Gonzalez, Cynthia R, Baselga-Carretero, Ignacio, Vega-Crespo, Agustin, Garcilazo, Ivan Perez, Sharon, Elad, Hu-Lieskovan, Siwen, Patel, Sapna P, Grossmann, Kenneth F, Moon, James, Wu, Michael C, and Ribas, Antoni

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Immunology, Clinical Research, Patient Safety, Minority Health, Clinical Trials and Supportive Activities, Cancer, 6.1 Pharmaceuticals, Humans, B7-H1 Antigen, CTLA-4 Antigen, Ipilimumab, Melanoma, Nivolumab, Medical and Health Sciences, Biomedical and clinical sciences, Health sciences
Abstract

In this randomized phase 2 trial, blockade of cytotoxic T-lymphocyte protein 4 (CTLA-4) with continuation of programmed death protein 1 (PD-1) blockade in patients with metastatic melanoma who had received front-line anti-PD-1 or therapy against programmed cell death 1 ligand 1 and whose tumors progressed was tested in comparison with CTLA-4 blockade alone. Ninety-two eligible patients were randomly assigned in a 3:1 ratio to receive the combination of ipilimumab and nivolumab, or ipilimumab alone. The primary endpoint was progression-free survival. Secondary endpoints included the difference in CD8 T cell infiltrate among responding and nonresponding tumors, objective response rate, overall survival and toxicity. The combination of nivolumab and ipilimumab resulted in a statistically significant improvement in progression-free survival over ipilimumab (hazard ratio = 0.63, 90% confidence interval (CI) = 0.41-0.97, one-sided P = 0.04). Objective response rates were 28% (90% CI = 19-38%) and 9% (90% CI = 2-25%), respectively (one-sided P = 0.05). Grade 3 or higher treatment-related adverse events occurred in 57% and 35% of patients, respectively, which is consistent with the known toxicity profile of these regimens. The change in intratumoral CD8 T cell density observed in the present analysis did not reach statistical significance to support the formal hypothesis tested as a secondary endpoint. In conclusion, primary resistance to PD-1 blockade therapy can be reversed in some patients with the combination of CTLA-4 and PD-1 blockade. Clinicaltrials.gov identifier: NCT03033576 .

Published
2023

2. Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma

Author

Patel, Sapna P, Othus, Megan, Chen, Yuanbin, Wright, G Paul, Yost, Kathleen J, Hyngstrom, John R, Hu-Lieskovan, Siwen, Lao, Christopher D, Fecher, Leslie A, Truong, Thach-Giao, Eisenstein, Jennifer L, Chandra, Sunandana, Sosman, Jeffrey A, Kendra, Kari L, Wu, Richard C, Devoe, Craig E, Deutsch, Gary B, Hegde, Aparna, Khalil, Maya, Mangla, Ankit, Reese, Amy M, Ross, Merrick I, Poklepovic, Andrew S, Phan, Giao Q, Onitilo, Adedayo A, Yasar, Demet G, Powers, Benjamin C, Doolittle, Gary C, In, Gino K, Kokot, Niels, Gibney, Geoffrey T, Atkins, Michael B, Shaheen, Montaser, Warneke, James A, Ikeguchi, Alexandra, Najera, Jose E, Chmielowski, Bartosz, Crompton, Joseph G, Floyd, Justin D, Hsueh, Eddy, Margolin, Kim A, Chow, Warren A, Grossmann, Kenneth F, Dietrich, Eliana, Prieto, Victor G, Lowe, Michael C, Buchbinder, Elizabeth I, Kirkwood, John M, Korde, Larissa, Moon, James, Sharon, Elad, Sondak, Vernon K, and Ribas, Antoni

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Patient Safety, Clinical Research, Clinical Trials and Supportive Activities, Cancer, 6.1 Pharmaceuticals, 6.4 Surgery, Humans, Adjuvants, Immunologic, Disease Progression, Melanoma, Neoadjuvant Therapy, Skin Neoplasms, Antineoplastic Agents, Immunological, Chemotherapy, Adjuvant, Medical and Health Sciences, General & Internal Medicine, Biomedical and clinical sciences, Health sciences
Abstract

BackgroundWhether pembrolizumab given both before surgery (neoadjuvant therapy) and after surgery (adjuvant therapy), as compared with pembrolizumab given as adjuvant therapy alone, would increase event-free survival among patients with resectable stage III or IV melanoma is unknown.MethodsIn a phase 2 trial, we randomly assigned patients with clinically detectable, measurable stage IIIB to IVC melanoma that was amenable to surgical resection to three doses of neoadjuvant pembrolizumab, surgery, and 15 doses of adjuvant pembrolizumab (neoadjuvant-adjuvant group) or to surgery followed by pembrolizumab (200 mg intravenously every 3 weeks for a total of 18 doses) for approximately 1 year or until disease recurred or unacceptable toxic effects developed (adjuvant-only group). The primary end point was event-free survival in the intention-to-treat population. Events were defined as disease progression or toxic effects that precluded surgery; the inability to resect all gross disease; disease progression, surgical complications, or toxic effects of treatment that precluded the initiation of adjuvant therapy within 84 days after surgery; recurrence of melanoma after surgery; or death from any cause. Safety was also evaluated.ResultsAt a median follow-up of 14.7 months, the neoadjuvant-adjuvant group (154 patients) had significantly longer event-free survival than the adjuvant-only group (159 patients) (P = 0.004 by the log-rank test). In a landmark analysis, event-free survival at 2 years was 72% (95% confidence interval [CI], 64 to 80) in the neoadjuvant-adjuvant group and 49% (95% CI, 41 to 59) in the adjuvant-only group. The percentage of patients with treatment-related adverse events of grades 3 or higher during therapy was 12% in the neoadjuvant-adjuvant group and 14% in the adjuvant-only group.ConclusionsAmong patients with resectable stage III or IV melanoma, event-free survival was significantly longer among those who received pembrolizumab both before and after surgery than among those who received adjuvant pembrolizumab alone. No new toxic effects were identified. (Funded by the National Cancer Institute and Merck Sharp and Dohme; S1801 ClinicalTrials.gov number, NCT03698019.).

Published
2023

3. BTK inhibition potentiates anti-PD-L1 treatment in murine melanoma: potential role for MDSC modulation in immunotherapy

Author

Sun, Steven H., Angell, Colin D., Savardekar, Himanshu, Sundi, Debasish, Abood, David, Benner, Brooke, DiVincenzo, Mallory J., Duggan, Megan, Choueiry, Fouad, Mace, Thomas, Trikha, Prashant, Lapurga, Gabriella, Johnson, Courtney, Carlson, Erick J., Chung, Catherine, Peterson, Blake R., Lianbo Yu, Zhao, Jing, Kendra, Kari L., and Carson, III, William E.

Published
2023
Full Text
View/download PDF

4. Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134

Author

Atkins, Michael B, Lee, Sandra J, Chmielowski, Bartosz, Tarhini, Ahmad A, Cohen, Gary I, Truong, Thach-Giao, Moon, Helen H, Davar, Diwakar, O'Rourke, Mark, Stephenson, Joseph J, Curti, Brendan D, Urba, Walter J, Brell, Joanna M, Funchain, Pauline, Kendra, Kari L, Ikeguchi, Alexandra P, Jaslowski, Anthony, Bane, Charles L, Taylor, Mark A, Bajaj, Madhuri, Conry, Robert M, Ellis, Robert J, Logan, Theodore F, Laudi, Noel, Sosman, Jeffrey A, Crockett, David G, Pecora, Andrew L, Okazaki, Ian J, Reganti, Sowjanya, Chandra, Sunandana, Guild, Samantha, Chen, Helen X, Streicher, Howard Z, Wolchok, Jedd D, Ribas, Antoni, and Kirkwood, John M

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Immunology, Health Disparities, Clinical Research, Precision Medicine, Cancer, Patient Safety, Clinical Trials and Supportive Activities, 6.1 Pharmaceuticals, 6.2 Cellular and gene therapies, Humans, Ipilimumab, Nivolumab, Proto-Oncogene Proteins B-raf, Prospective Studies, Melanoma, Pyridones, Oximes, Disease Progression, Mitogen-Activated Protein Kinase Kinases, Antineoplastic Combined Chemotherapy Protocols, Skin Neoplasms, Mutation, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

PurposeCombination programmed cell death protein 1/cytotoxic T-cell lymphocyte-4-blockade and dual BRAF/MEK inhibition have each shown significant clinical benefit in patients with BRAFV600-mutant metastatic melanoma, leading to broad regulatory approval. Little prospective data exist to guide the choice of either initial therapy or treatment sequence in this population. This study was conducted to determine which initial treatment or treatment sequence produced the best efficacy.Patients and methodsIn a phase III trial, patients with treatment-naive BRAFV600-mutant metastatic melanoma were randomly assigned to receive either combination nivolumab/ipilimumab (arm A) or dabrafenib/trametinib (arm B) in step 1, and at disease progression were enrolled in step 2 to receive the alternate therapy, dabrafenib/trametinib (arm C) or nivolumab/ipilimumab (arm D). The primary end point was 2-year overall survival (OS). Secondary end points were 3-year OS, objective response rate, response duration, progression-free survival, crossover feasibility, and safety.ResultsA total of 265 patients were enrolled, with 73 going onto step 2 (27 in arm C and 46 in arm D). The study was stopped early by the independent Data Safety Monitoring Committee because of a clinically significant end point being achieved. The 2-year OS for those starting on arm A was 71.8% (95% CI, 62.5 to 79.1) and arm B 51.5% (95% CI, 41.7 to 60.4; log-rank P = .010). Step 1 progression-free survival favored arm A (P = .054). Objective response rates were arm A: 46.0%; arm B: 43.0%; arm C: 47.8%; and arm D: 29.6%. Median duration of response was not reached for arm A and 12.7 months for arm B (P < .001). Crossover occurred in 52% of patients with documented disease progression. Grade ≥ 3 toxicities occurred with similar frequency between arms, and regimen toxicity profiles were as anticipated.ConclusionCombination nivolumab/ipilimumab followed by BRAF and MEK inhibitor therapy, if necessary, should be the preferred treatment sequence for a large majority of patients.

Published
2023

5. Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk MelanomaAdjuvant Pembrolizumab in High-Risk Melanoma

Author

Grossmann, Kenneth F, Othus, Megan, Patel, Sapna P, Tarhini, Ahmad A, Sondak, Vernon K, Knopp, Michael V, Petrella, Teresa M, Truong, Thach-Giao, Khushalani, Nikhil I, Cohen, Justine V, Buchbinder, Elizabeth I, Kendra, Kari, Funchain, Pauline, Lewis, Karl D, Conry, Robert M, Chmielowski, Bartosz, Kudchadkar, Ragini R, Johnson, Douglas B, Li, Hongli, Moon, James, Eroglu, Zeynep, Gastman, Brian, Kovacsovics-Bankowski, Magdalena, Gunturu, Krishna S, Ebbinghaus, Scot W, Ahsan, Sama, Ibrahim, Nageatte, Sharon, Elad, Korde, Larissa A, Kirkwood, John M, and Ribas, Antoni

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Cancer, Comparative Effectiveness Research, Clinical Trials and Supportive Activities, Clinical Research, Patient Safety, 6.1 Pharmaceuticals, Adjuvants, Immunologic, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological, Humans, Ipilimumab, Melanoma, Risk Assessment, Biochemistry and cell biology, Oncology and carcinogenesis
Abstract

We conducted a randomized phase III trial to evaluate whether adjuvant pembrolizumab for one year (647 patients) improved recurrence-free survival (RFS) or overall survival (OS) in comparison with high-dose IFNα-2b for one year or ipilimumab for up to three years (654 patients), the approved standard-of-care adjuvant immunotherapies at the time of enrollment for patients with high-risk resected melanoma. At a median follow-up of 47.5 months, pembrolizumab was associated with significantly longer RFS than prior standard-of-care adjuvant immunotherapies [HR, 0.77; 99.62% confidence interval (CI), 0.59-0.99; P = 0.002]. There was no statistically significant association with OS among all patients (HR, 0.82; 96.3% CI, 0.61-1.09; P = 0.15). Proportions of treatment-related adverse events of grades 3 to 5 were 19.5% with pembrolizumab, 71.2% with IFNα-2b, and 49.2% with ipilimumab. Therefore, adjuvant pembrolizumab significantly improved RFS but not OS compared with the prior standard-of-care immunotherapies for patients with high-risk resected melanoma.SignificanceAdjuvant PD-1 blockade therapy decreases the rates of recurrence, but not survival, in patients with surgically resectable melanoma, substituting the prior standard-of-care immunotherapies for this cancer. See related commentary by Smithy and Shoushtari, p. 599. This article is highlighted in the In This Issue feature, p. 587.

Published
2022

12. Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial

Author

Kim, Sungjune, Wuthrick, Evan, Blakaj, Dukagjin, Eroglu, Zeynep, Verschraegen, Claire, Thapa, Ram, Mills, Matthew, Dibs, Khaled, Liveringhouse, Casey, Russell, Jeffery, Caudell, Jimmy J, Tarhini, Ahmad, Markowitz, Joseph, Kendra, Kari, Wu, Richard, Chen, Dung-Tsa, Berglund, Anders, Michael, Lauren, Aoki, Mia, Wang, Min-Hsuan, Hamaidi, Imene, Cheng, Pingyan, de la Iglesia, Janis, Slebos, Robbert J, Chung, Christine H, Knepper, Todd C, Moran-Segura, Carlos M, Nguyen, Jonathan V, Perez, Bradford A, Rose, Trevor, Harrison, Louis, Messina, Jane L, Sondak, Vernon K, Tsai, Kenneth Y, Khushalani, Nikhil I, and Brohl, Andrew S

Published
2022
Full Text
View/download PDF

14. Supplementary Figure 8 from Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton's Tyrosine Kinase

Author

Savardekar, Himanshu, primary, Allen, Carter, primary, Jeon, Hyeongseon, primary, Li, Jianying, primary, Quiroga, Dionisia, primary, Schwarz, Emily, primary, Wu, Richard C., primary, Zelinskas, Sara, primary, Lapurga, Gabriella, primary, Abreo, Alexander, primary, Stiff, Andrew, primary, Shaffer, Jami, primary, Blaser, Bradley W., primary, Old, Matthew, primary, Wesolowski, Robert, primary, Xin, Gang, primary, Kendra, Kari L., primary, Chung, Dongjun, primary, and Carson, William E., primary

Published
2024
Full Text
View/download PDF

15. Supplementary Table 2 from Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton's Tyrosine Kinase

Author

Savardekar, Himanshu, primary, Allen, Carter, primary, Jeon, Hyeongseon, primary, Li, Jianying, primary, Quiroga, Dionisia, primary, Schwarz, Emily, primary, Wu, Richard C., primary, Zelinskas, Sara, primary, Lapurga, Gabriella, primary, Abreo, Alexander, primary, Stiff, Andrew, primary, Shaffer, Jami, primary, Blaser, Bradley W., primary, Old, Matthew, primary, Wesolowski, Robert, primary, Xin, Gang, primary, Kendra, Kari L., primary, Chung, Dongjun, primary, and Carson, William E., primary

Published
2024
Full Text
View/download PDF

16. Supplementary Figure 6 from Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton's Tyrosine Kinase

Author

Savardekar, Himanshu, primary, Allen, Carter, primary, Jeon, Hyeongseon, primary, Li, Jianying, primary, Quiroga, Dionisia, primary, Schwarz, Emily, primary, Wu, Richard C., primary, Zelinskas, Sara, primary, Lapurga, Gabriella, primary, Abreo, Alexander, primary, Stiff, Andrew, primary, Shaffer, Jami, primary, Blaser, Bradley W., primary, Old, Matthew, primary, Wesolowski, Robert, primary, Xin, Gang, primary, Kendra, Kari L., primary, Chung, Dongjun, primary, and Carson, William E., primary

Published
2024
Full Text
View/download PDF

17. Supplementary Figure 2 from Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton's Tyrosine Kinase

Author

Savardekar, Himanshu, primary, Allen, Carter, primary, Jeon, Hyeongseon, primary, Li, Jianying, primary, Quiroga, Dionisia, primary, Schwarz, Emily, primary, Wu, Richard C., primary, Zelinskas, Sara, primary, Lapurga, Gabriella, primary, Abreo, Alexander, primary, Stiff, Andrew, primary, Shaffer, Jami, primary, Blaser, Bradley W., primary, Old, Matthew, primary, Wesolowski, Robert, primary, Xin, Gang, primary, Kendra, Kari L., primary, Chung, Dongjun, primary, and Carson, William E., primary

Published
2024
Full Text
View/download PDF

18. Supplementary Figure 3 from Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton's Tyrosine Kinase

Author

Savardekar, Himanshu, primary, Allen, Carter, primary, Jeon, Hyeongseon, primary, Li, Jianying, primary, Quiroga, Dionisia, primary, Schwarz, Emily, primary, Wu, Richard C., primary, Zelinskas, Sara, primary, Lapurga, Gabriella, primary, Abreo, Alexander, primary, Stiff, Andrew, primary, Shaffer, Jami, primary, Blaser, Bradley W., primary, Old, Matthew, primary, Wesolowski, Robert, primary, Xin, Gang, primary, Kendra, Kari L., primary, Chung, Dongjun, primary, and Carson, William E., primary

Published
2024
Full Text
View/download PDF

19. Supplementary Figure 5 from Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton's Tyrosine Kinase

Author

Savardekar, Himanshu, primary, Allen, Carter, primary, Jeon, Hyeongseon, primary, Li, Jianying, primary, Quiroga, Dionisia, primary, Schwarz, Emily, primary, Wu, Richard C., primary, Zelinskas, Sara, primary, Lapurga, Gabriella, primary, Abreo, Alexander, primary, Stiff, Andrew, primary, Shaffer, Jami, primary, Blaser, Bradley W., primary, Old, Matthew, primary, Wesolowski, Robert, primary, Xin, Gang, primary, Kendra, Kari L., primary, Chung, Dongjun, primary, and Carson, William E., primary

Published
2024
Full Text
View/download PDF

20. Supplementary Table 1 from Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton's Tyrosine Kinase

Author

Savardekar, Himanshu, primary, Allen, Carter, primary, Jeon, Hyeongseon, primary, Li, Jianying, primary, Quiroga, Dionisia, primary, Schwarz, Emily, primary, Wu, Richard C., primary, Zelinskas, Sara, primary, Lapurga, Gabriella, primary, Abreo, Alexander, primary, Stiff, Andrew, primary, Shaffer, Jami, primary, Blaser, Bradley W., primary, Old, Matthew, primary, Wesolowski, Robert, primary, Xin, Gang, primary, Kendra, Kari L., primary, Chung, Dongjun, primary, and Carson, William E., primary

Published
2024
Full Text
View/download PDF

21. Supplementary Figure 4 from Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton's Tyrosine Kinase

Author

Savardekar, Himanshu, primary, Allen, Carter, primary, Jeon, Hyeongseon, primary, Li, Jianying, primary, Quiroga, Dionisia, primary, Schwarz, Emily, primary, Wu, Richard C., primary, Zelinskas, Sara, primary, Lapurga, Gabriella, primary, Abreo, Alexander, primary, Stiff, Andrew, primary, Shaffer, Jami, primary, Blaser, Bradley W., primary, Old, Matthew, primary, Wesolowski, Robert, primary, Xin, Gang, primary, Kendra, Kari L., primary, Chung, Dongjun, primary, and Carson, William E., primary

Published
2024
Full Text
View/download PDF

22. Data from Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton's Tyrosine Kinase

Author

Savardekar, Himanshu, primary, Allen, Carter, primary, Jeon, Hyeongseon, primary, Li, Jianying, primary, Quiroga, Dionisia, primary, Schwarz, Emily, primary, Wu, Richard C., primary, Zelinskas, Sara, primary, Lapurga, Gabriella, primary, Abreo, Alexander, primary, Stiff, Andrew, primary, Shaffer, Jami, primary, Blaser, Bradley W., primary, Old, Matthew, primary, Wesolowski, Robert, primary, Xin, Gang, primary, Kendra, Kari L., primary, Chung, Dongjun, primary, and Carson, William E., primary

Published
2024
Full Text
View/download PDF

23. Supplementary Table 6 from Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton's Tyrosine Kinase

Author

Savardekar, Himanshu, primary, Allen, Carter, primary, Jeon, Hyeongseon, primary, Li, Jianying, primary, Quiroga, Dionisia, primary, Schwarz, Emily, primary, Wu, Richard C., primary, Zelinskas, Sara, primary, Lapurga, Gabriella, primary, Abreo, Alexander, primary, Stiff, Andrew, primary, Shaffer, Jami, primary, Blaser, Bradley W., primary, Old, Matthew, primary, Wesolowski, Robert, primary, Xin, Gang, primary, Kendra, Kari L., primary, Chung, Dongjun, primary, and Carson, William E., primary

Published
2024
Full Text
View/download PDF

24. Supplementary Table 5 from Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton's Tyrosine Kinase

Author

Savardekar, Himanshu, primary, Allen, Carter, primary, Jeon, Hyeongseon, primary, Li, Jianying, primary, Quiroga, Dionisia, primary, Schwarz, Emily, primary, Wu, Richard C., primary, Zelinskas, Sara, primary, Lapurga, Gabriella, primary, Abreo, Alexander, primary, Stiff, Andrew, primary, Shaffer, Jami, primary, Blaser, Bradley W., primary, Old, Matthew, primary, Wesolowski, Robert, primary, Xin, Gang, primary, Kendra, Kari L., primary, Chung, Dongjun, primary, and Carson, William E., primary

Published
2024
Full Text
View/download PDF

25. Supplementary Figure 1 from Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton's Tyrosine Kinase

Author

Savardekar, Himanshu, primary, Allen, Carter, primary, Jeon, Hyeongseon, primary, Li, Jianying, primary, Quiroga, Dionisia, primary, Schwarz, Emily, primary, Wu, Richard C., primary, Zelinskas, Sara, primary, Lapurga, Gabriella, primary, Abreo, Alexander, primary, Stiff, Andrew, primary, Shaffer, Jami, primary, Blaser, Bradley W., primary, Old, Matthew, primary, Wesolowski, Robert, primary, Xin, Gang, primary, Kendra, Kari L., primary, Chung, Dongjun, primary, and Carson, William E., primary

Published
2024
Full Text
View/download PDF

26. Supplementary Figure 7 from Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton's Tyrosine Kinase

Author

Savardekar, Himanshu, primary, Allen, Carter, primary, Jeon, Hyeongseon, primary, Li, Jianying, primary, Quiroga, Dionisia, primary, Schwarz, Emily, primary, Wu, Richard C., primary, Zelinskas, Sara, primary, Lapurga, Gabriella, primary, Abreo, Alexander, primary, Stiff, Andrew, primary, Shaffer, Jami, primary, Blaser, Bradley W., primary, Old, Matthew, primary, Wesolowski, Robert, primary, Xin, Gang, primary, Kendra, Kari L., primary, Chung, Dongjun, primary, and Carson, William E., primary

Published
2024
Full Text
View/download PDF

27. Supplementary Table 3 from Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton's Tyrosine Kinase

Author

Savardekar, Himanshu, primary, Allen, Carter, primary, Jeon, Hyeongseon, primary, Li, Jianying, primary, Quiroga, Dionisia, primary, Schwarz, Emily, primary, Wu, Richard C., primary, Zelinskas, Sara, primary, Lapurga, Gabriella, primary, Abreo, Alexander, primary, Stiff, Andrew, primary, Shaffer, Jami, primary, Blaser, Bradley W., primary, Old, Matthew, primary, Wesolowski, Robert, primary, Xin, Gang, primary, Kendra, Kari L., primary, Chung, Dongjun, primary, and Carson, William E., primary

Published
2024
Full Text
View/download PDF

28. Supplementary Table 4 from Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton's Tyrosine Kinase

Author

Savardekar, Himanshu, primary, Allen, Carter, primary, Jeon, Hyeongseon, primary, Li, Jianying, primary, Quiroga, Dionisia, primary, Schwarz, Emily, primary, Wu, Richard C., primary, Zelinskas, Sara, primary, Lapurga, Gabriella, primary, Abreo, Alexander, primary, Stiff, Andrew, primary, Shaffer, Jami, primary, Blaser, Bradley W., primary, Old, Matthew, primary, Wesolowski, Robert, primary, Xin, Gang, primary, Kendra, Kari L., primary, Chung, Dongjun, primary, and Carson, William E., primary

Published
2024
Full Text
View/download PDF

30. A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancers.

Author

Algazi, Alain P., Moon, James, Lao, Christopher D., Chmielowski, Bartosz, Kendra, Kari L., Lewis, Karl D., Gonzalez, Rene, Kim, Kevin, Godwin, John E., Curti, Brendan D., Latkovic-Taber, Michaella, Lomeli, Shirley H., Gufford, Brandon T., Scumpia, Philip O., Lo, Roger S., Othus, Megan, and Ribas, Antoni

Subjects
BRAF genes, CANCER patients
Published
2024
Full Text
View/download PDF

31. Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton’s Tyrosine Kinase

Author

Savardekar, Himanshu, primary, Allen, Carter, additional, Jeon, Hyeongseon, additional, Li, Jianying, additional, Quiroga, Dionisia, additional, Schwarz, Emily, additional, Wu, Richard C., additional, Zelinskas, Sara, additional, Lapurga, Gabriella, additional, Abreo, Alexander, additional, Stiff, Andrew, additional, Shaffer, Jami, additional, Blaser, Bradley W., additional, Old, Matthew, additional, Wesolowski, Robert, additional, Xin, Gang, additional, Kendra, Kari L., additional, Chung, Dongjun, additional, and Carson, William E., additional

Published
2023
Full Text
View/download PDF

32. Association Between Pretreatment Chest Imaging and Immune Checkpoint Inhibitor Pneumonitis Among Patients With Lung Cancer

Author

Wong, Alexander, primary, Riley, Maria, additional, Zhao, Songzhu, additional, Zimmer, Jessica, additional, Viveiros, Matthew, additional, Wang, Jing Gennie, additional, Esguerra, Vincent, additional, Li, Mingjia, additional, Lopez, Gabrielle, additional, Kendra, Kari, additional, Carbone, David P., additional, He, Kai, additional, Alahmadi, Asrar, additional, Kaufman, Jacob, additional, Memmott, Regan M., additional, Shields, Peter G., additional, Brownstein, Jeremy, additional, Haglund, Karl, additional, Welliver, Meng, additional, Otterson, Gregory A., additional, Presley, Carolyn J., additional, Wei, Lai, additional, Owen, Dwight H., additional, and Ho, Kevin, additional

Published
2023
Full Text
View/download PDF

35. Hedgehog pathway inhibitors for locally advanced and metastatic basal cell carcinoma: A real-world single-center retrospective review.

Author

Patel, Shivani, Armbruster, Heather, Pardo, Gretchen, Archambeau, Brianna, Kim, Na Hyun, Jeter, Joanne, Wu, Richard, Kendra, Kari, Contreras, Carlo M., Spaccarelli, Natalie, Dulmage, Brittany, Pootrakul, Llana, Carr, David R., and Verschraegen, Claire

Subjects
BASAL cell carcinoma, HEDGEHOG signaling proteins, CALCIUM supplements, SPASMS, RETROSPECTIVE studies
Abstract

Basal cell carcinoma (BCC) is highly curable by surgical excision or radiation. In rare cases, BCC can be locally destructive or difficult to surgically remove. Hedgehog inhibition (HHI) with vismodegib or sonidegib induces a 50–60% response rate. Long-term toxicity includes muscle spasms and weight loss leading to dose decreases. This retrospective chart review also investigates the impact of CoQ10 and calcium supplementation in patients treated with HHI drugs at a single academic medical center from 2012 to 2022. We reviewed the charts of adult patients diagnosed with locally advanced or metastatic BCC treated with vismodegib or sonidegib primarily for progression-free survival (PFS). Secondary objectives included overall survival, BCC-specific survival, time to and reasons for discontinuation, overall response rate, safety and tolerability, use of CoQ10 and calcium supplements, and insurance coverage. Of 55 patients assessable for outcome, 34 (61.8%) had an overall clinical benefit, with 25 (45.4%) having a complete response and 9 (16.3%) a partial response. Stable disease was seen in 14 (25.4%) and 7 (12.7%) progressed. Of the 34 patients who responded to treatment, 9 recurred. Patients who were rechallenged with HHI could respond again. The median overall BCC-specific survival rate at 5 years is 89%. Dose reductions or discontinuations for vismodegib and sonidegib occurred in 59% versus 24% of cases, or 30% versus 9% of cases, respectively. With CoQ10 and calcium supplementation, only 17% required a dose reduction versus 42% without. HHI is highly effective for treating advanced BCC but may require dosing decreases. Sonidegib was better tolerated than vismodegib. CoQ10 and calcium supplementation can effectively prevent muscle spasms. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

36. ASSOCIATION BETWEEN PRE-TREATMENT CHEST IMAGING AND IMMUNE CHECKPOINT INHIBITOR PNEUMONITIS IN LUNG CANCER

Author

WONG, ALEXANDER, primary, RILEY, MARIA, additional, ZHAO, SONGZHU, additional, ZIMMER, JESSICA, additional, VIVEIROS, MATTHEW, additional, WANG, JING G, additional, ESGUERRA, VINCENT G, additional, LI, MINGJIA, additional, LOPEZ, GABRIELLE, additional, OTTERSON, GREGORY, additional, KENDRA, KARI, additional, PRESLEY, CAROLYN, additional, WEI, LAI, additional, OWEN, DWIGHT, additional, and HO, KEVIN, additional

Published
2023
Full Text
View/download PDF

37. Risk Factors for Immune Checkpoint Inhibitor Immunotherapy Toxicity Among Older Adults with Cancer

Author

Johns, Andrew C, primary, Yang, Mike, additional, Wei, Lai, additional, Grogan, Madison, additional, Spakowicz, Daniel, additional, Patel, Sandipkumar H, additional, Li, Mingjia, additional, Husain, Marium, additional, Kendra, Kari L, additional, Otterson, Gregory A, additional, Rosko, Ashley E, additional, Andersen, Barbara L, additional, Carbone, David P, additional, Owen, Dwight H, additional, and Presley, Carolyn J, additional

Published
2023
Full Text
View/download PDF

38. Abstract CT009: S1512: High response rate with single agent anti-PD-1 in patients with metastatic desmoplastic melanoma

Author

Kendra, Kari, primary, Bellasea, Shay, additional, Eroglu, Zeynep, additional, Hu-Lieskovan, Siwen, additional, Campbell, Katie M., additional, Carson, William, additional, Wada, David, additional, Plaza, Jose A., additional, Sosman, Jeffrey, additional, IN, Gino K., additional, Ikeguchi, Alexandra, additional, Hyngstrom, John, additional, Brohl, Andres, additional, Khushalani, Nikhil I., additional, Markowitz, Joseph, additional, Negrea, George, additional, Kasbari, Samer, additional, Doolittle, Gary C., additional, Swami, Umang, additional, Roberts, Toni, additional, Patel, Sapna P., additional, Sharon, Elad, additional, Moon, James, additional, Wu, Michael C., additional, and Ribas, Antoni, additional

Published
2023
Full Text
View/download PDF

39. Abstract 3764: Expression patterns of microRNAs and associated target genes in ulcerated primary cutaneous melanoma

Author

Schwarz, Emily, primary, DiVincenzo, Mallory J., additional, Ren, Casey, additional, Barricklow, Zoe, additional, Moufawad, Maribelle, additional, Yu, Lianbo, additional, Fadda, Paolo, additional, Angell, Colin, additional, Zelinskas, Sara, additional, Sun, Steven, additional, Howard, John H., additional, Chung, Catherine, additional, Slingluff, Craig, additional, Gru, Alejandro A., additional, Kendra, Kari, additional, and Carson, William E., additional

Published
2023
Full Text
View/download PDF

40. Data from Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma

Author

Grossmann, Kenneth F., primary, Othus, Megan, primary, Patel, Sapna P., primary, Tarhini, Ahmad A., primary, Sondak, Vernon K., primary, Knopp, Michael V., primary, Petrella, Teresa M., primary, Truong, Thach-Giao, primary, Khushalani, Nikhil I., primary, Cohen, Justine V., primary, Buchbinder, Elizabeth I., primary, Kendra, Kari, primary, Funchain, Pauline, primary, Lewis, Karl D., primary, Conry, Robert M., primary, Chmielowski, Bartosz, primary, Kudchadkar, Ragini R., primary, Johnson, Douglas B., primary, Li, Hongli, primary, Moon, James, primary, Eroglu, Zeynep, primary, Gastman, Brian, primary, Kovacsovics-Bankowski, Magdalena, primary, Gunturu, Krishna S., primary, Ebbinghaus, Scot W., primary, Ahsan, Sama, primary, Ibrahim, Nageatte, primary, Sharon, Elad, primary, Korde, Larissa A., primary, Kirkwood, John M., primary, and Ribas, Antoni, primary

Published
2023
Full Text
View/download PDF

41. Abstract 3275: Combination of talimogene laherparepvec (T-VEC) with pembrolizumab (pembro) in advanced melanoma patients following progression on a prior PD-1 inhibitor: SWOG S1607

Author

Hu-Lieskovan, Siwen, primary, Moon, James, additional, Hyngstrom, John, additional, Campbell, Katie M., additional, In, Gino K., additional, Logan, Theodore F., additional, Kendra, Kari L., additional, Wang, Ding M., additional, Johnson, Douglas B., additional, Doolittle, Gary C., additional, Tan, Alan, additional, Silk, Ann W., additional, Grossmann, Kenneth F., additional, Ryan, Christopher W., additional, Patel, Sapna P., additional, Bellasea, Shay, additional, Wu, Michael C., additional, Kirkwood, John M., additional, Chen, Helen X., additional, and Ribas, Antoni, additional

Published
2023
Full Text
View/download PDF

42. Supplementary Data from Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma

Author

Grossmann, Kenneth F., primary, Othus, Megan, primary, Patel, Sapna P., primary, Tarhini, Ahmad A., primary, Sondak, Vernon K., primary, Knopp, Michael V., primary, Petrella, Teresa M., primary, Truong, Thach-Giao, primary, Khushalani, Nikhil I., primary, Cohen, Justine V., primary, Buchbinder, Elizabeth I., primary, Kendra, Kari, primary, Funchain, Pauline, primary, Lewis, Karl D., primary, Conry, Robert M., primary, Chmielowski, Bartosz, primary, Kudchadkar, Ragini R., primary, Johnson, Douglas B., primary, Li, Hongli, primary, Moon, James, primary, Eroglu, Zeynep, primary, Gastman, Brian, primary, Kovacsovics-Bankowski, Magdalena, primary, Gunturu, Krishna S., primary, Ebbinghaus, Scot W., primary, Ahsan, Sama, primary, Ibrahim, Nageatte, primary, Sharon, Elad, primary, Korde, Larissa A., primary, Kirkwood, John M., primary, and Ribas, Antoni, primary

Published
2023
Full Text
View/download PDF

43. Abstract 4527: CD8 T cell-melanoma cell interactions in response and resistance to ipilimumab plus nivolumab: Biopsy analysis of SWOG S1616

Author

Campbell, Katie M., primary, Kuklinski, Lawrence, additional, Bustami, Zaid, additional, Maxey, Jessica, additional, Medina, Egmidio, additional, Santulli-Marotto, Sandra, additional, Gonzalez, Cynthia R., additional, Aldeen, Nataly Naser, additional, Kendra, Kari, additional, Patel, Sapna, additional, Hu-Lieskovan, Siwen, additional, Moon, James, additional, Bellasea, Shay, additional, Spencer, Christine N., additional, Thompson, Marshall A., additional, Wu, Michael, additional, Vanderwalde, Ari, additional, Scumpia, Philip O., additional, and Ribas, Antoni, additional

Published
2023
Full Text
View/download PDF

49. Data from The Exportin-1 Inhibitor Selinexor Exerts Superior Antitumor Activity when Combined with T-Cell Checkpoint Inhibitors

Author

Farren, Matthew R., primary, Hennessey, Rebecca C., primary, Shakya, Reena, primary, Elnaggar, Omar, primary, Young, Gregory, primary, Kendra, Kari, primary, Landesman, Yosef, primary, Elloul, Sivan, primary, Crochiere, Marsha, primary, Klebanov, Boris, primary, Kashyap, Trinayan, primary, Burd, Christin E., primary, and Lesinski, Gregory B., primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results